170 related articles for article (PubMed ID: 21373647)
1. Vinflunine: a fluorinated vinca alkaloid for bladder cancer therapy.
Gerullis H
Drugs Today (Barc); 2011 Jan; 47(1):17-25. PubMed ID: 21373647
[TBL] [Abstract][Full Text] [Related]
2. Vinflunine as second-line treatment in platin-resistant metastatic urothelial carcinoma: a review.
Gerullis H; Ecke T; Eimer C; Wishahi M; Otto T
Anticancer Drugs; 2011 Jan; 22(1):9-17. PubMed ID: 20948429
[TBL] [Abstract][Full Text] [Related]
3. Vinflunine.
Frampton JE; Moen MD
Drugs; 2010 Jul; 70(10):1283-93. PubMed ID: 20568834
[TBL] [Abstract][Full Text] [Related]
4. Vinflunine.
Prescrire Int; 2011 Jan; 20(112):11-3. PubMed ID: 21462785
[TBL] [Abstract][Full Text] [Related]
5. Clinical activity of vinflunine in transitional cell carcinoma of the urothelium and other solid tumors.
Bellmunt J; Delgado FM; George C
Semin Oncol; 2008 Jun; 35(3 Suppl 3):S34-43. PubMed ID: 18538178
[TBL] [Abstract][Full Text] [Related]
6. Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy.
Bellmunt J; Fougeray R; Rosenberg JE; von der Maase H; Schutz FA; Salhi Y; Culine S; Choueiri TK
Ann Oncol; 2013 Jun; 24(6):1466-72. PubMed ID: 23419284
[TBL] [Abstract][Full Text] [Related]
7. Vinflunine, the latest Vinca alkaloid in clinical development. A review of its preclinical anticancer properties.
Kruczynski A; Hill BT
Crit Rev Oncol Hematol; 2001 Nov; 40(2):159-73. PubMed ID: 11682323
[TBL] [Abstract][Full Text] [Related]
8. Vinflunine: drug safety evaluation of this novel synthetic vinca alkaloid.
Schutz FA; Bellmunt J; Rosenberg JE; Choueiri TK
Expert Opin Drug Saf; 2011 Jul; 10(4):645-53. PubMed ID: 21524237
[TBL] [Abstract][Full Text] [Related]
9. A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN).
Bellmunt J; Kerst JM; Vázquez F; Morales-Barrera R; Grande E; Medina A; González Graguera MB; Rubio G; Anido U; Fernández Calvo O; González-Billalabeitia E; Van den Eertwegh AJM; Pujol E; Perez-Gracia JL; González Larriba JL; Collado R; Los M; Maciá S; De Wit R;
Ann Oncol; 2017 Jul; 28(7):1517-1522. PubMed ID: 28419193
[TBL] [Abstract][Full Text] [Related]
10. The first Slovak experience with second-line vinflunine in advanced urothelial carcinomas.
Palacka P; Mego M; Obertova J; Chovanec M; Sycova-Mila Z; Mardiak J
Klin Onkol; 2014; 27(6):429-33. PubMed ID: 25493582
[TBL] [Abstract][Full Text] [Related]
11. Vinflunine in Metastatic Urothelial Carcinoma of the Bladder in Progression after a Platinum-Containing Regimen.
De Luca R; Profita G; Vella M; Cicero G
Oncology; 2019; 97(6):341-347. PubMed ID: 31461721
[TBL] [Abstract][Full Text] [Related]
12. [Activity and efficacy of vinflunine in metastatic carcinoma of the bladder after failure of adjuvant treatment: description of a clinical case].
Morelli F
Recenti Prog Med; 2015 Jun; 106(6):e300-5. PubMed ID: 26076423
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen.
Culine S; Theodore C; De Santis M; Bui B; Demkow T; Lorenz J; Rolland F; Delgado FM; Longerey B; James N
Br J Cancer; 2006 May; 94(10):1395-401. PubMed ID: 16622447
[TBL] [Abstract][Full Text] [Related]
14. Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules.
Ngan VK; Bellman K; Panda D; Hill BT; Jordan MA; Wilson L
Cancer Res; 2000 Sep; 60(18):5045-51. PubMed ID: 11016627
[TBL] [Abstract][Full Text] [Related]
15. Vinflunine in the treatment of advanced bladder cancer.
Mamtani R; Vaughn DJ
Expert Rev Anticancer Ther; 2011 Jan; 11(1):13-20. PubMed ID: 21166506
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of vinflunine: effector pathways and potential for synergies.
Braguer D; Barret JM; McDaid H; Kruczynski A
Semin Oncol; 2008 Jun; 35(3 Suppl 3):S13-21. PubMed ID: 18538174
[TBL] [Abstract][Full Text] [Related]
17. Vinflunine: a new microtubule inhibitor agent.
Bennouna J; Delord JP; Campone M; Nguyen L
Clin Cancer Res; 2008 Mar; 14(6):1625-32. PubMed ID: 18347163
[TBL] [Abstract][Full Text] [Related]
18. Vinflunine: review of a new vinca alkaloid and its potential role in oncology.
Ng JS
J Oncol Pharm Pract; 2011 Sep; 17(3):209-24. PubMed ID: 20584744
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, metabolites, and preclinical safety of vinflunine.
Lobert S; Puozzo C
Semin Oncol; 2008 Jun; 35(3 Suppl 3):S28-33. PubMed ID: 18538176
[TBL] [Abstract][Full Text] [Related]
20. Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid.
Kruczynski A; Barret JM; Etiévant C; Colpaert F; Fahy J; Hill BT
Biochem Pharmacol; 1998 Mar; 55(5):635-48. PubMed ID: 9515574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
